<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250517065774N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-13</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Effects of exercise training and sports drink on cellular markers in soccer players</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the role of eight weeks of SAQ and sprint interval training on mitochondrial indices and cell-free DNA concentration in soccer players along with consumption of sports drinks.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/92157</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Basic scienece, Randomization description: To use the random number table, the researcher will first determine the table's reading direction. Then the numbers will be considered for different groups. For example, numbers 14-00 for group A, numbers 15-29 for intervention B, numbers 44-30 for group C, and 45-59 for group D. Then, we will place our hands on one of the numbers and move in one of the predetermined directions. The numbers will be recorded and assigned to four groups: SAQ group (agility/speed drills); SIT (intermittent sprints) with stretching recovery and Spirulina drink consumption; SAQ group (agility/speed drills) with stretching recovery and Spirulina drink consumption; and SIT (intermittent sprints) with stretching recovery and Spirulina drink consumption. To conceal the random allocation, the coded-box method with random sequences will be used. This method uses several boxes numbered in a random sequence. It will be ensured that the boxes are sufficiently sealed, identical in appearance, and equal in weight, Blinding description: In this study, the analyst, statistician, specialist assistant, coach and physiologist were unaware of the entire study process. The blinding process included allocation concealment through sealed envelopes and spirulina drink consumption, standardized exercise training protocols, and outcome assessment by an independent blinded team with automated digital devices coupled with an emergency controlled disclosure mechanism designed for emergencies. In order to blind the consumption of spirulina drink, all the participants in the recovery stage are given a simple drink in dark bottles so that the color of the drink is not clear.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Mitochondrial indices and cell free DNA concentration and cell death.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: SAQ group (Agility/Speed ​​Drills): Perform SAQ (Speed, Agility, Quickness) exercises and include a 10-minute warm-up with light jogging and dynamic movements, 10-30 meter sprint speed exercises, agility and direction changes, and quickness and reaction exercises. The intensity of the exercise is set in the range of 85-95% of maximum heart rate and the duration of each session is 30-40 minutes. Intervention 2: Intervention group 2: SIT group: The SIT protocol consisted of four sets of maximal-intensity sprints interspersed with short recovery periods between sets and longer recovery periods between sets. Intervention 3: Intervention group 3: SAQ group (agility/speed drills) + recovery with stretching and consumption of 500 mg of spirulina drink. Intervention 4: Intervention group 4: SIT group + recovery with stretching and consumption of 500 mg of Spirulina drink.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Undecided - It is not yet known if there will be a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Navid Abedpoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshgah Boulevard, Arghavanieh, Jay Sharqi Street, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>39998-81551</zip>
        <telephone>+98 31 3535 2900</telephone>
        <email>abedpoor.navid@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Navid Abedpoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Azad Univesity Of Isfahan (Khorasgan) Branch -Daneshgah blvd, Arghavanieh, East Jey St, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>39998-81551</zip>
        <telephone>+98 31 3535 2900</telephone>
        <email>abedpoor.navid@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Male
Age of 14-15 years old
No musculoskeletal abnormalities
With informed consent from the player's parents.
No supplements/medications (except a standard multivitamin)
Completion of the PAR-Q questionnaire and normal pre-exercise ECG</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>15 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of known cardiovascular or pulmonary diseases
Presence of acute or chronic injuries in limbs over the past 6 months
Smoking or alcohol consumption
Having metabolic disorders such as diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: SAQ group (Agility/Speed ​​Drills): Perform SAQ (Speed, Agility, Quickness) exercises and include a 10-minute warm-up with light jogging and dynamic movements, 10-30 meter sprint speed exercises, agility and direction changes, and quickness and reaction exercises. The intensity of the exercise is set in the range of 85-95% of maximum heart rate and the duration of each session is 30-40 minutes.</i_keyword>
      <i_keyword>Intervention group 2: SIT group: The SIT protocol consisted of four sets of maximal-intensity sprints interspersed with short recovery periods between sets and longer recovery periods between sets.</i_keyword>
      <i_keyword>Intervention group 3: SAQ group (agility/speed drills) + recovery with stretching and consumption of 500 mg of spirulina drink.</i_keyword>
      <i_keyword>Intervention group 4: SIT group + recovery with stretching and consumption of 500 mg of Spirulina drink.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gene expression of PGC-1a in peripheral blood mononuclear cells in young soccer players. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Real-time qPCR.</prim_outcome>
      <prim_outcome>Citrate synthetase concentration. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Elisa Kit.</prim_outcome>
      <prim_outcome>Serum cfDNA concentration. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: cfDNA concentration assay kit.</prim_outcome>
      <prim_outcome>Gene expression of COX in peripheral blood mononuclear cells in young soccer players. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Real-time qPCR.</prim_outcome>
      <prim_outcome>Gene expression of MFN2 in peripheral blood mononuclear cells in young soccer players. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Real-time qPCR.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Aerobic power. Timepoint: At the beginning and end of 8 weeks of study. Method of measurement: Yo-Yo Aerobic Endurance Test Level 1.</sec_outcome>
      <sec_outcome>Anaerobic Resistance. Timepoint: At the beginning and end of 8 weeks of study. Method of measurement: RAST field test.</sec_outcome>
      <sec_outcome>Dribbling speed skills in Soccer. Timepoint: At the beginning and end of 8 weeks of study. Method of measurement: Ronaldo's dribbling speed test (Hulichi et al., 2014; Wood, 2024).</sec_outcome>
      <sec_outcome>Peak power and Average power. Timepoint: At the beginning and end of 8 weeks of study. Method of measurement: Reciprocal Sargent test using the formula: Peak power (W) = 78.5 x VJ (cm) + 60.6 x mass (kg) -15.3 x height (cm) -1308 and the formula: Average power (W) = 41.4 x VJ (cm) + 31.2 x mass (kg) -13.9 x height (cm) + 431.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-28</approval_date>
        <contact_name>Ethics Committee on Research Islamic Azad University - Isfahan Branch (Khorasgan)</contact_name>
        <contact_address>Daneshgah Boulevard, Arghavanieh, East Gey Street, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
